Protocol Ledger

NCT03580655 · Phase II · COMPLETED

(PATHFINDER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, in Patients With Advanced Systemic Mastocytosis

Interventional Phase II clinical trial protocol NCT03580655 sponsored by Blueprint Medicines in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2018-11-21 Enrollment: 107 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT03580655
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)107 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT03580655
Protocol FieldVerified Registry Value
NCT IdentifierNCT03580655
Consolidated Lead SponsorBlueprint Medicines
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusCOMPLETED
Registered Enrollment107 participants (ACTUAL)
Registered Start Date2018-11-21
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI